PCSK9 and sarcopenia: Previous studies already proved separately the benefit of Mstn and PCSK9 modulation in different clinical settings; in sarcopenia, the silencing of Mstn has been shown to restrain the proteasomal-mediated catabolism of intracellular proteins, the muscle wasting, and to potentiate basal antioxidant enzyme levels [30].